Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 8/20 | 0.33 |
| ▸ | HTR2B | P41595 | 7/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.33 |
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.31 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25963066 | 0.78 | CHRM2 (0.41) | HSD11B1PARP2 | |
| SCHEMBL31266652 | 0.78 | MAPK1 (0.38) | HSD11B1 | |
| SCHEMBL26884894 | 0.74 | PARP1 (0.38) | HSD11B1PARP1PARP2 | |
| SCHEMBL26881042 | 0.74 | GRIN2D (0.31) | HSD11B1 | |
| SCHEMBL20952557 | 0.72 | HRH3 (0.41) | TP53HTR2CHTR2BHSD11B1HTR2A | |
| Hydrochloric Acid SCHEMBL20475439 | 0.70 | HRH3 (0.41) | TP53HSD11B1 | |
| SCHEMBL25966764 | 0.70 | CTSD (0.48) | TP53FPR2 | |
| SCHEMBL30948807 | 0.69 | HTR2C (0.38) | HTR2CHTR2BHTR2APARP1 | |
| SCHEMBL726957 | 0.68 | HTR2C (0.40) | TP53HTR2CHTR2BHSD11B1HTR2A | |
| SCHEMBL994623 | 0.68 | HTR2C (0.40) | TP53HTR2CHTR2BHTR2AFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | TP53 1795/4885HTR2C 3480/4885HTR2B 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.